Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
Trial details
- Registry ID
- NCT04984278
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as GW-1000-02; Sativex
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple SclerosisNCT04984278 | Jazz Pharmaceuticals | Phase 3 | Terminated | 2022-11-11Actual |
| Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple SclerosisNCT04203498 | Jazz Pharmaceuticals | Phase 3 | Terminated | 2023-02-10Actual |
| Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple SclerosisNCT04657666 | Jazz Pharmaceuticals | Phase 3 | Completed | 2022-05-04Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |